Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.
企業コードKARD
会社名Kardigan Inc
上場日Jun 18, 2026
最高経営責任者「CEO」Gianakakos (Tassos Anastasios)
従業員数420
証券種類Ordinary Share
決算期末Jun 18
本社所在地506 Carnegie Center Drive, Suite 201
都市PRINCETON JUNCTION
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号08540
電話番号14155733220
ウェブサイトhttp://www.kardigan.bio
企業コードKARD
上場日Jun 18, 2026
最高経営責任者「CEO」Gianakakos (Tassos Anastasios)